0001415889-24-006165.txt : 20240301 0001415889-24-006165.hdr.sgml : 20240301 20240301175049 ACCESSION NUMBER: 0001415889-24-006165 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240223 FILED AS OF DATE: 20240301 DATE AS OF CHANGE: 20240301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reents Scott T CENTRAL INDEX KEY: 0001937048 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35565 FILM NUMBER: 24712000 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AbbVie Inc. CENTRAL INDEX KEY: 0001551152 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320375147 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 BUSINESS PHONE: (847) 932-7900 MAIL ADDRESS: STREET 1: 1 NORTH WAUKEGAN ROAD CITY: NORTH CHICAGO STATE: IL ZIP: 60064 4 1 form4-03012024_050325.xml X0508 4 2024-02-23 0001551152 AbbVie Inc. ABBV 0001937048 Reents Scott T 1 N. WAUKEGAN ROAD NORTH CHICAGO IL 60064 false true false false EVP, CHIEF FINANCIAL OFFICER 0 Common Stock, $0.01 par value 2024-02-23 4 M 0 14140 61.36 A 41205 D Common Stock, $0.01 par value 2024-02-23 4 S 0 14140 177.44 D 27065 D Common Stock, $0.01 par value 2024-02-28 4 F 0 11634 178.99 D 15431 D Option (Right to buy) 61.36 2024-02-23 4 M 0 14140 61.36 D 2018-02-16 2027-02-15 Common Stock 14140 17380 D The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $177.41 to $177.55, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. T.O. Odutayo, attorney-in-fact for Scott T. Reents 2024-03-01